Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
In this study, we comprehensively evaluated the clinical utility of Trop2 PET/CT (68Ga-MY6349 PET/CT) imaging for detecting recurrent and metastatic thyroid cancer, and the results were compared with those of 68Ga-FAPI PET/CT. The primary objective of this study was to evaluate the patient-based sensitivity of 68Ga-MY6349 PET/CT in detecting recurrent and metastatic thyroid cancer. The secondary objectives included its overall specificity, lesion-based diagnostic performance, comparative tumor uptake relative to 68Ga-FAPI PET/CT, and the impact on clinical management.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorosłe osoby w wieku 18 lat i starsze
- •Historia wcześniejszego leczenia raka tarczycy (po usunięciu tarczycy, z terapią radioaktywną lub bez)
- •Podejrzenie nawrotu choroby widoczne na poprzednich badaniach lub potwierdzane podwyższonymi wskaźnikami w krwi
- •Zaplanowane już obie procedury skanowania (68Ga-MY6349 i 68Ga-FAPI PET/CT)
- •Umiejętność udzielenia pisemnej zgody na udział w badaniu
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Obecność innego nowotworu (drugiego pierwotnego guza)
- •Niemożliwość lub niechęć do podpisania zgody na badanie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 90 Years
- Last updated (source)
- August 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000
Xiamen, China
Trial contact
Haojun Chen, MD, PhD
Hao Fu, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.